Di Yi Cai Jing·2025-10-26 11:15Group 1 - Leading multinational medical companies are evolving from mere technology providers to significant co-creators in China's healthcare ecosystem [1] - AstraZeneca has launched a new global strategic R&D center in Beijing, which includes an AI and data science center to accelerate the transition of early drug research results to clinical development [2] - Medtronic's newly established digital healthcare innovation base in Beijing will focus on developing AI and big data-based disease management solutions [2] Group 2 - Pfizer has opened an R&D open innovation center in Shanghai, aimed at supporting local universities, biotech companies, hospitals, and clinical research institutions to expedite innovation [2] - Pfizer's CEO highlighted that China has captured 30% of the global drug development market over the past decade due to its rapid R&D processes [2][3] - The number of innovative drug pipelines in China has increased from approximately 60 a decade ago to around 1,200 today, with Chinese biopharmaceutical companies recruiting clinical trial patients 2 to 5 times faster than their U.S. counterparts [3] Group 3 - Multinational medical giants are increasing R&D and supply chain localization investments in China, leading to the emergence of numerous therapies originating from Chinese innovation [4] - The upcoming China International Import Expo will serve as a significant platform for multinational companies to participate in building a health ecosystem in China [4] - Boehringer Ingelheim plans to invest over 5 billion RMB in R&D in China over the next five years, aiming for synchronized global approvals for new drugs and indications [4] Group 4 - Gilead Sciences is actively advancing local R&D, with 16 ongoing projects, including 10 in oncology and 6 in non-oncology, aiming for synchronized global development [5] - Gilead's projects include initiatives to improve HIV treatment success rates in collaboration with local health associations [4][5]